Argus Research analyst Jasper Hellweg upgrades $AbbVie (ABBV.US)$ to a buy rating.
According to TipRanks data, the analyst has a success rate of 56.8% and a total average return of 8.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie has reported another strong quarter, and attention is now shifting towards emraclidine and the outlook for the year 2025.
The firm has adjusted its outlook on AbbVie following the company's strong Q3 results and an increased revenue forecast for 2024. This positive shift is underpinned by an enhanced earnings projection for 2025. Despite this optimistic view, a balanced perspective is maintained when assessing the company's long-term growth prospects in relation to its present market valuation.
Following a robust third-quarter report characterized by surpassing expectations and upward revisions, optimism in the growth outlook is bolstered. This sentiment is further reinforced by increased projections, primarily driven by the performance of Rinvoq and Skyrizi, although tempered by moderated expectations for aesthetics and Humira sales.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
阿格斯分析師Jasper Hellweg上調$艾伯維公司 (ABBV.US)$至買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為56.8%，總平均回報率為8.1%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
艾伯維公司再次報告了強勁的一個季度，目前注意力正在轉向emraclidine和2025年的前景。
公司根據艾伯維公司強勁的第三季度業績和2024年增加的營業收入預測調整了其展望。這種積極變化得到了2025年盈利預期的支撐。儘管持有這種樂觀態度，在評估公司的長期增長前景與當前市場估值的關係時，保持了一種平衡的觀點。
在強勁的第三季度報告中，預期的超越和上調特徵使增長前景的樂觀情緒得到加強。這種情緒在增加的預測進一步增強，主要由Rinvoq和Skyrizi的表現推動，儘管在美學和Humira銷售預期方面受到調和的影響。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
